Molecular mechanisms of castration-resistant prostate cancer progressed from prostate cancer by androgen deprivation treatment
10.3760/cma.j.issn.1673-422X.2018.08.013
- VernacularTitle:雄激素剥脱治疗后前列腺癌发展为去势抵抗性前列腺癌的分子机制
- Author:
Yaozong XU
1
;
Xiao GU
;
Fei WANG
;
Xuefei DING
Author Information
1. 116044 大连医科大学研究生院;江苏省苏北人民医院泌尿外科
- Keywords:
Prostatic neoplasms;
Receptors,androgen;
Carcinoma,neuroendocrine;
Neoplastic stem cells;
Transformation
- From:
Journal of International Oncology
2018;45(8):506-509
- CountryChina
- Language:Chinese
-
Abstract:
Androgen deprivation treatment (ADT) is the gold standard of care for patients with locally advanced or metastatic hormone-sensitive prostate cancer.However,most of these patients have developed to the castration-resistant prostate cancer (CRPC) after months or years through a series of different molecular mechanisms during ADT.So far,CRPC is still incurable and deadly,therefore,it is very important for researchers to study different molecular mechanism in the occurrence and development of CRPC,which may provide some new directions for targeted therapy.
